--- title: "West Pharmaceutical | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 872.3 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/293605931.md" datetime: "2026-07-23T11:17:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293605931.md) - [en](https://longbridge.com/en/news/293605931.md) - [zh-HK](https://longbridge.com/zh-HK/news/293605931.md) --- # West Pharmaceutical | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 872.3 M Revenue: As of FY2026 Q2, the actual value is USD 872.3 M, beating the estimate of USD 839.98 M. EPS: As of FY2026 Q2, the actual value is USD 2.15, beating the estimate of USD 2.072. EBIT: As of FY2026 Q2, the actual value is USD 177.9 M. #### Net Sales West Pharmaceutical Services, Inc. reported net sales of $872.3 million for the second quarter of 2026, an increase of 13.8% compared to the prior-year period, with organic growth at 12.7%. #### Segment Revenue (Q2 2026) - **Proprietary Products**: Net sales increased by 16.6% to $722.6 million, with organic growth of 15.5%. - **High-Value Product (HVP) Components**: Net sales were $424.1 million, up 19.4% (18.4% organic), accounting for 49% of total company net sales. - **HVP Delivery Devices**: Net sales were $131.2 million, up 29.6% (29.2% organic), accounting for 15% of total company net sales. - **Standard Products**: Net sales were $167.3 million, up 2.4% (0.7% organic), accounting for 19% of total company net sales. - **West Vantage**: Net sales increased by 2.0% to $149.7 million, with organic growth of 0.8%, accounting for 17% of total company net sales. #### Revenue by Market Group (Q2 2026) - **Biologics**: Revenue was $374.8 million, with a 30.3% year-over-year (YoY) change and 29.2% organic change. - **Pharma**: Revenue was $205.0 million, with a 3.3% YoY change and 1.6% organic change. - **Generics**: Revenue was $142.8 million, with a 6.9% YoY change and 6.7% organic change. #### Revenue by Geography (Q2 2026) - **Americas**: Revenue was $388.7 million, with an 11.2% YoY change and 10.6% organic change. - **Europe, Middle East, Africa**: Revenue was $399.8 million, with a 14.3% YoY change and 12.1% organic change. - **Asia Pacific**: Revenue was $83.8 million, with a 24.9% YoY change and 27.0% organic change. #### Net Income Net income for the second quarter was $154.0 million. For the six months ended June 30, 2026, net income was $292.8 million. #### Gross Profit and Margin Consolidated gross profit was $329.2 million for the second quarter, representing a gross profit margin of 37.7%, an increase of 200 basis points (bps) year-over-year. **Proprietary Products**: Gross profit was $308.0 million, with a gross profit margin of 42.6%, up 250 bps YoY. **West Vantage**: Gross profit was $21.2 million, with a gross profit margin of 14.2%, a decrease of -330 bps YoY. #### Operating Profit and Margin Reported operating profit for the second quarter was $179.1 million, with a reported operating profit margin of 20.5%. Adjusted operating profit was $197.4 million, with an adjusted operating profit margin of 22.6%, up 230 bps compared to Q2 2025. **Proprietary Products**: Operating profit was $211.9 million, with an operating profit margin of 29.3%, an increase of 320 bps YoY. **West Vantage**: Operating profit was $12.9 million, with an operating profit margin of 8.6%, down -350 bps YoY.For the six months ended June 30, 2026, reported operating profit was $356.2 million, and adjusted operating profit was $378.4 million. #### Operating Costs (Q2 2026) - Research and development expenses were $19.7 million. - Selling, general and administrative expenses totaled $117.6 million. - Other expense (income), net, was $12.8 million. #### Cash Flow (Six Months Ended June 30, 2026) Operating cash flow was $213.9 million. Capital expenditures were $85.9 million. Free cash flow was $128.0 million. #### Share Repurchases and Dividends During the first six months of 2026, West Pharmaceutical Services, Inc. repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share. A third-quarter 2026 dividend of $0.22 per share was declared on July 21, 2026. #### Other Financial Data (As of June 30, 2026) - Total Assets: $4,076.4 million. - Total Liabilities: $1,086.2 million. - Total Equity: $2,990.2 million. - Cash and cash equivalents: $435.8 million. #### Outlook / Guidance West Pharmaceutical Services, Inc. is raising its full-year 2026 net sales guidance to a range of $3.345 billion to $3.380 billion, representing reported growth of 8.8% to 10.0% and organic growth of 10.0% to 11.0%. Full-year 2026 adjusted-diluted EPS guidance is increased to a range of $8.85 to $9.05, and capital spending guidance remains unchanged at $250 million to $275 million. For the third quarter of 2026, net sales are expected to be between $820 million and $835 million, with adjusted-diluted EPS projected in the range of $2.14 to $2.24, and the estimated tax rate for 2026 is approximately 19%. ### Related Stocks - [WST.US](https://longbridge.com/en/quote/WST.US.md) ## Related News & Research - [WST: Q2 2026 delivered double-digit sales and EPS growth, prompting raised full-year guidance](https://longbridge.com/en/news/293594456.md) - [West Pharmaceutical Services announces Q3 2026 distribution of R$ 0.02 per unit](https://longbridge.com/en/news/293488427.md) - [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md) - [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md) - [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)